Abstract
Agonist treatment causes desensitization of many G proteincoupled receptor systems. Recent advances have delineated changes in receptors in the desensitization response; however, the role of G proteins remains unclear. We investigated the role of phosphorylation of Gαq/11 proteins in agonist-induced desensitization of serotonin 2A (5-HT2A) receptors. In an embryonic rat cortical cell line (A1A1v), 24-h treatment with 100 nM (-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl (DOI), a 5-HT2A/2C receptor agonist, decreased DOI-stimulated inositol phosphate accumulation and increased the phosphorylation of Gαq/11 proteins, as demonstrated by immunoprecipitation of Gαq/11 and both incorporation of 32P phosphate and labeling with a S/T/Y phosphorylation-dependent antibody. Treatment with DOI for 30 min induced desensitization but did not increase phosphorylation of Gαq/11 proteins, suggesting that different mechanisms are involved in desensitization after short- and long-term treatments. Mutation of S154A in a protein kinase C (PKC) and calcium/calmodulin dependent kinase (CaMK) consensus site in Gα11 significantly reduced DOI-stimulated phosphorylation of Gα11 and DOI-induced desensitization of 5-HT2A receptor signaling. Inhibition of PKC and CaMK attenuated phosphorylation of Gαq/11 proteins and DOI-induced desensitization of 5-HT2A receptors. Expression of Gα11 S154D, a phosphorylation mimic, reduced DOI-stimulated inositol phosphate accumulation. DOI treatment for 24 h also produced heterologous desensitization, as indicated by decreased bradykinin-stimulated inositol phosphate accumulation. These data suggest that phosphorylation of Gα11 protein by PKC and CaMK contributes to agonistinduced homologous desensitization of 5-HT2A receptor signaling as well as heterologous desensitization. The phosphorylation of Gα protein represents a novel mechanism involved in regulation of receptor signaling and agonist-induced desensitization of G protein-coupled receptors.
Footnotes
-
This work was supported by United States Public Health Service grant MH068612.
-
ABBREVIATIONS: 5-HT, serotonin (5-hydroxytryptamine); DOI, (-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl; PLC, phospholipase C; PKC, protein kinase C; CaMK, Ca2+-calmodulin dependent kinase; DMEM, Dulbecco's modified Eagle's medium; PMA, phorbol 12-myristate 13-acetate; KN-93, 2-(N-(2-hydroxyethyl)-N-(4-methoxybenzenesulfonyl))amino-N-(4-chlorocinnamyl)-N-methylbenzylamine; TBS, Tris-buffered saline; IOD, integrated optical density; PI, phosphoinositol; IP, inositol phosphate; ANOVA, analysis of variance; MDL 100,907, (±)-α -(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidinemethanol; ANOVA, analysis of variance.
- Received June 22, 2006.
- Accepted October 20, 2006.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|